Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II, Open-Label, Dose-Escalation Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1

Trial Profile

A Phase I/II, Open-Label, Dose-Escalation Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 09 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rasdegafusp-alfa (Primary) ; Poly ICLC; Resiquimod
  • Indications Advanced breast cancer; Bladder cancer; Malignant melanoma; Myeloma; Non-small cell lung cancer; Ovarian cancer; Sarcoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Celldex Therapeutics Inc
  • Most Recent Events

    • 06 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 29 Oct 2012 Positive results were presented at the Annual Meeting of the Society for Immunotherapy in October 2012, and were reported in a Celldex Therapeutics media release.
    • 10 Aug 2012 Celldex expects to present results from the phase I portion of the trial in the fourth quarter of 2012.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top